SETTING: Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) in South Africa have suffered as centralized, in-patient treatment programs struggle to cope with rising prevalence and human immunodeficiency virus (HIV) co-infection rates. A new treatment model is needed to expand treatment capacity and improve MDR-TB and HIV outcomes. OBJECTIVE: To describe the design and preliminary results of an integrated, home-based MDR-TB-HIV treatment program created in rural KwaZulu-Natal. METHOD: In 2008, a decentralized center was established to provide out-patient MDR-TB and HIV treatment. Nurses, community health workers and family supporters have been trained to administer injections, provide adherence support and monitor adverse reactions in patients' homes. Physicians assess clinical response, adherence and the severity of adverse reactions to MDR-TB and HIV treatment at monthly follow-up visits. Treatment outcomes are assessed by monthly cultures and CD4 and viral load every 6 months. RESULTS: Of 80 patients initiating MDR-TB treatment from February 2008 to April 2010, 66 were HIV-co-infected. Retention has been high (only 5% defaults, 93% of visits attended), and preliminary outcomes have been favorable (77% cured/still on treatment, 82% undetectable viral load). Few patients have required escalation of care (9%), had severe adverse events (8%) or died (6%). CONCLUSION: Integrated, home-based treatment for MDR-TB and HIV is a promising treatment model to expand capacity and achieve improved outcomes in rural, resource-poor and high HIV prevalent settings.
SETTING: Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) in South Africa have suffered as centralized, in-patient treatment programs struggle to cope with rising prevalence and human immunodeficiency virus (HIV) co-infection rates. A new treatment model is needed to expand treatment capacity and improve MDR-TB and HIV outcomes. OBJECTIVE: To describe the design and preliminary results of an integrated, home-based MDR-TB-HIV treatment program created in rural KwaZulu-Natal. METHOD: In 2008, a decentralized center was established to provide out-patient MDR-TB and HIV treatment. Nurses, community health workers and family supporters have been trained to administer injections, provide adherence support and monitor adverse reactions in patients' homes. Physicians assess clinical response, adherence and the severity of adverse reactions to MDR-TB and HIV treatment at monthly follow-up visits. Treatment outcomes are assessed by monthly cultures and CD4 and viral load every 6 months. RESULTS: Of 80 patients initiating MDR-TB treatment from February 2008 to April 2010, 66 were HIV-co-infected. Retention has been high (only 5% defaults, 93% of visits attended), and preliminary outcomes have been favorable (77% cured/still on treatment, 82% undetectable viral load). Few patients have required escalation of care (9%), had severe adverse events (8%) or died (6%). CONCLUSION: Integrated, home-based treatment for MDR-TB and HIV is a promising treatment model to expand capacity and achieve improved outcomes in rural, resource-poor and high HIV prevalent settings.
Authors: Rajesh Gupta; J Peter Cegielski; Marcos A Espinal; Myriam Henkens; Jim Y Kim; Catherina S B Lambregts-Van Weezenbeek; Jong-Wook Lee; Mario C Raviglione; Pedro G Suarez; Francis Varaine Journal: Trop Med Int Health Date: 2002-11 Impact factor: 2.622
Authors: Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona Journal: Lancet Date: 2010-05-22 Impact factor: 79.321
Authors: A J Manders; A Banerjee; H W van den Borne; A D Harries; G J Kok; F M Salaniponi Journal: Int J Tuberc Lung Dis Date: 2001-09 Impact factor: 2.373
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti Journal: PLoS One Date: 2009-09-25 Impact factor: 3.240
Authors: Jaime Libes; Oliver Oruko; Fatmah Abdallah; Jessie Githanga; James Ndung'u; Joyce Musimbi; Festus Njuguna; Kirtika Patel; John White; Jason R Axt; James A O'Neill; Martha Shrubsole; Ming Li; Harold N Lovvorn Journal: Pediatr Blood Cancer Date: 2014-11-08 Impact factor: 3.167
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson Journal: Int J Tuberc Lung Dis Date: 2013-01-14 Impact factor: 2.373
Authors: James C M Brust; N Sarita Shah; Theo L van der Merwe; Sheila Bamber; Yuming Ning; Moonseong Heo; Anthony P Moll; Marian Loveday; Umesh G Lalloo; Gerald H Friedland; Neel R Gandhi Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: M R O'Donnell; A Daftary; M Frick; Y Hirsch-Moverman; K R Amico; M Senthilingam; A Wolf; J Z Metcalfe; P Isaakidis; J L Davis; J R Zelnick; J C M Brust; N Naidu; M Garretson; D R Bangsberg; N Padayatchi; G Friedland Journal: Int J Tuberc Lung Dis Date: 2016-04 Impact factor: 2.373
Authors: S K Heysell; O B Ogarkov; S Zhdanova; E Zorkaltseva; S Shugaeva; J Gratz; S Vitko; E D Savilov; M E Koshcheyev; E R Houpt Journal: Int J Tuberc Lung Dis Date: 2016-02 Impact factor: 2.373